Serenoa repens (Saw Palmetto): A systematic review of adverse events

Drug Safety

Volumn 32, Issue 8, 2009, Pages 637-647

  Agbabiaka, Taofikat B ^a   Pittler, Max H ^a,b   Wider, Barbara ^a   Ernst, Edzard ^a  

^a PENINSULA MEDICAL SCHOOL   (United Kingdom)

^b INSTITUTE FOR QUALITY AND EFFICIENCY IN HEALTH CARE IQWIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALFUZOSIN; AMLODIPINE; ATORVASTATIN; CARVEDILOL; CYNARA SCOLYMUS EXTRACT; FERROUS SULFATE; FINASTERIDE; GLUCOSAMINE; HERBACEOUS AGENT; HYDROCHLOROTHIAZIDE; IBUPROFEN; INSULIN; LERCANIDIPINE; MEPARTRICIN; METOPROLOL TARTRATE; OLANZAPINE; PERINDOPRIL; PLACEBO; PRAVASTATIN; PRAZOSIN; PROSTAGUTT MONO; PROSTAGUTT UNO; PROSTAMOL UNO; PROSTASERENE; PROSTESS UNO; RAMIPRIL; SABAL EXTRACT; SABALVIT UNO; SITA; TALSO UNO; TAMSULOSIN; UNCLASSIFIED DRUG; VALPROIC ACID; VERAPAMIL;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ANEMIA; BRAIN HEMATOMA; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CHOLESTATIC HEPATITIS; CLINICAL TRIAL; COMMON COLD; CREATINE KINASE BLOOD LEVEL; DELIRIUM; DEPRESSION; DERMATITIS; DIARRHEA; DIZZINESS; DRUG EFFECT; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG INFORMATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG SYNTHESIS; DRUG WITHDRAWAL; DYSPEPSIA; EJACULATION DISORDER; FALLING; FATIGUE; FLATULENCE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GYNECOMASTIA; HEALTH CARE ORGANIZATION; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; IMPOTENCE; IN VITRO STUDY; JAUNDICE; LIBIDO DISORDER; LIVER ABSCESS; LOWER URINARY TRACT SYMPTOM; MYALGIA; NAUSEA; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; RHINITIS; SABAL; SIDE EFFECT; SKIN DISEASE; STOMACH DISCOMFORT; STOMACH DISEASE; STOMACH PAIN; SUICIDE ATTEMPT; SYSTEMATIC REVIEW; THORAX PAIN; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URINARY DYSFUNCTION; VERTIGO; VOMITING;

CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; HUMANS; MALE; PLANT EXTRACTS; PROSTATIC HYPERPLASIA; SERENOA; UROLOGIC DISEASES;

EID: 67650439353     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/00002018-200932080-00003     Document Type: Review

References (55)

1. Murray M, Pizzorno J. Encyclopedia of natural medicine. Seattle (WA): John Bastyr University Publishing, 1994
2. Lowe FC, Ku JC. Phytotherapy in treatment of benign prostatic hyperplasia: a critical review. Urology 1996; 48: 12-20
3. Wilt TJ, Ishani A, Stark G. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA 1998; 280: 1604-9
4. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50: 1306-14
5. Kupelian V, Wei JT, O'Leary MP, et al. Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) survey. Arch Intern Med 2006; 166: 2381-7
6. Gerber GS, Kuznetsov D, Johnson BC, et al. Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms. Urology 2001; 58: 960-4
7. Vallancien G, Pariente P. Treatment of lower urinary tract symptoms suggestive of benign prostatic obstruction in real life practice in France. Prostate Cancer Prostatic Dis 2001; 4: 124-31
8. Blumenthal M, Busse W, Hall T, editors. The complete German Commission E monographs: therapeutic guide to herbal medicines. Newton (MA): Integrative Medicine Communications, 1998
9. Di Silverio F, D'Eramo G, Lubrano C, et al. Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients. Eur Urol 1992; 21: 309-14
10. Boyle P, Robertson C, Lowe F, et al. Meta-analysis of clinical trials of permixon in the treatment of symptomatic benign prostatic hyperplasia. Urology 2000; 55: 533-9
11. Champault G, Bonnard AM, Cauquil J, et al. Medical treatment of prostatic adenoma. Controlled trial: PA 109 vs placebo in 110 patients. Ann Urol 1984; 18: 407-10
12. Marks LS. 5a reductase: history and clinical importance. Rev Urol 2004; Suppl. 9: S11-21
13. Habib FK, Wyllie MG. Not all brands are created equal: a comparison of selected components of different brands of Serenoa repens extract. Prostate Cancer Prostatic Dis 2004; 7: 195-200
14. Reynolds JEF, editor. Serenoa repens. Martindale: the extra pharmacopoeia. London: The Royal Pharmaceutical Society, 1996: 1506
15. Sinclair RD, Mallari RS, Tate B. Sensitization to saw palmetto and minoxidil in separate topical extemporaneous treatments for androgenetic alopecia. Australas J Dermatol 2002; 43: 311-2
16. Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther 2004; 76: 428-40
17. Al-Shukri SH, Deschaseaux P, Kuzmin IV, et al. Early urodynamic effects of the lipido-sterolic extract of Serenoa repens (permixon®) in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 2000; 3: 195-9
18. Boccafoschi C, Annoscia S. Serenoa repens extract and placebo in prostatic benign hyperplasia: clinical results. Urologia 1983; 50: 1257-68
19. Carraro JC, Raynaud JP, Koch G, et al. Comparison of phytotherapy (permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate 1996; 29: 231-40
20. Champault G, Patel JC, Bonnard AM. A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia. Br J Clin Pharmacol 1984; 18: 461-2
21. Cukier J, Ducassou J, Le Guillou M, et al. Permixon® versus placebo: résultats d'une étude multicentrique. Comptes Rendus de Therapeut Pharmacol Clin 1985; 4: 15-21
22. Debruyne F, Koch G, Boyle P, et al. Comparison of a phytotherapeutic agent (permixon) with an alpha-blocker (tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Prog Urol 2002; 12: 384-92
23. Debruyne F, Boyle P, Calais da Silva F, et al. Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients: PERMAL study subset analysis. Prog Urol 2004; 14: 326-31
24. Descotes JL, Rambeaud JJ, Deschaseaux P, et al. Placebocontrolled evaluation of the efficacy and tolerability of permixon® in benign prostatic hyperplasia after exclusion of placebo responders. Clin Drug Investig 1995; 9: 291-7
25. Mandressi S, Tarallo U, Maggioni A, et al. Medical treatment of benign prostatic hyperplasia: efficacy of the extract of Serenoa repens (permixon®) compared to that of the extract of Pygeum africanum and placebo. Urologia 1983; 50: 752-7
26. Pytel YA, Vinarov A, Lopatkin N, et al. Long-term clinical and biologic effects of the lipidosterolic extract of Serenoa repens in patients with symptomatic benign prostatic hyperplasia. Adv Ther 2002; 19: 297-306
27. Reece Smith H, Menon A, Smart CJ, et al. The value of permixon in benign prostatic hypertrophy. Br J Urol 1986; 58: 36-40
28. Stepanov VN, Siniakova LA, Sarrazin B, et al. Efficacy and tolerability of the lipidosterolic extract of Serenoa repens (permixon) in benign prostatic hyperplasia: a double-blind comparison of two dosage regimens. Adv Ther 1999; 16: 231-41
29. Strauch G, Perles P, Vergult G, et al. Comparison of finasteride (proscar) and Serenoa repens (permixon) in the inhibition of 5-alpha reductase in healthy male volunteers. Eur Urol 1994; 26: 247-52
30. Tasca A, Barulli M, Cavazzana A, et al. Treatment of obstructive symptomatology caused by prostatic adenoma with an extract of Serenoa repens: double-blind clinical study vs placebo. Minerva Urol Nefrol 1985; 37: 87-91
31. Aliaev IuG, Vinarov AZ, Lokshin KL, et al. Five-year experience in treating patients with prostatic hyperplasia patients with permixone (Serenoa Repens Pierre Fabre Medicament) [in Russian]. Urologia 2002; 1: 23-5
32. Goepel M, Dinh L, Mitchell A, et al. Do saw palmetto extracts block human alpha1-adrenoceptor subtypes in vivo? Prostate 2001; 46: 226-32
33. Braeckman J, Denis L, de Leval J, et al. Double-blind, placebo-controlled study of the plant extract Serenoa repens in the treatment of benign hyperplasia of the prostate. Eur J Clin Res 1997; 9: 247-59
34. Braeckman J, Bruhwyler J, Vandekerckhove K, et al. Efficacy and safety of the extract of Serenoa repens in the treatment of benign prostatic hyperplasia: therapeutic equivalence between twice and once daily dosage forms. Phytother Res 1997; 11: 558-63
35. Redecker KD. Sabal-extrakt WS 1473 bei benigner prostatahyperplasie. Extracta Urologica 1998; 21: 23-5
36. Ziegler H, Holscher A. Efficacy of saw palmetto fruit extract 1473 in patients with alken stage I-II benign prostatic hyperplasia: open multicentre study. Jatros Uro 1998; 14: 34-3
37. Aliaev IuG, Vinarov AZ, Lokshin KL, et al. Efficiency and safety of prostamol-uno in patients with chronic abacterial prostatitis. Urologia 2006; 1: 47-50
38. Breza J, Kliment J, Valansky L, et al. Prostamol uno(alcohol extract of the fruits of Serenoa repens) in the treatment of symptomatic benign prostatic hyperplasia. Lek Obz 2005; 54: 139-44
39. Roveda S, Colombo P. Clinical controlled trial on therapeutical bioequivalence and tolerability of Serenoa repens oral capsules 160mg or rectal capsules 640 mg. Arch Med Interna 1994; 46: 61-75
40. Avins AL, Bent S, Staccone S, et al. A detailed safety assessment of a saw palmetto extract. Complement Ther Med 2008; 16 (3): 147-54
41. Bent S, Kane C, Shinohara K, et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med 2006; 354: 557-66
42. Prager N, Bickett K, French N, et al. Randomized, doubleblind, placebo-controlled trial to determine the effectiveness of botanically derived inhibitors of 5-alpha-reductase in the treatment of androgenetic alopecia. J Altern Complement Med 2002; 8: 143-52
43. Willetts KE, Clements MS, Champion S, et al. Serenoa repens extract for benign prostate hyperplasia: a randomized controlled trial. BJU Int 2003; 92: 267-70
44. Grasso M, Montesano A, Buonaguidi A, et al. Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia. Arch Esp Urol 1995; 48: 97-103
45. Kaplan SA, Volpe MA, Te AE. A prospective, 1-year trial using saw palmetto versus finasteride in the treatment of category III prostatitis/chronic pelvic pain syndrome. J Urol 2004; 171: 284-8
46. Adriazola Semino M, Lozano Ortega JL, García Cobo E, et al. Symptomatic treatment of benign hypertrophy of the prostate: comparative study of prazosin and Serenoa repens. Arch Esp Urol 1992; 45: 211-3
47. Comar OB, Di Rienzo A. Mepartricin vs. Serenoa repens: double-blind study in 20 cases of benign prostate hypertrophy. Rivista Italiana di Biologia e Medicina 1986; 6: 122-5
48. Hizli F, Uygur MC. A prospective study of the efficacy of Serenoa repens, tamsulosin, and Serenoa repens plus tamsulosin treatment for patients with benign prostate hyperplasia. Int Urol Nephrol 2007; 39: 879-86
49. Cheema P, El-Mefty O, Jazieh AR. Intraoperative haemorrhage associated with the use of extract of saw palmetto herb: a case report and review of literature. J Intern Med 2001; 250: 167-9
50. Jibrin I, Erinle A, Saidi A, et al. Saw palmetto-induced pancreatitis. South Med J 2006; 99: 611-2
51. Yeu E, Grostern R. Saw palmetto and intraoperative floppyiris syndrome. J Cataract Refract Surg 2007; 33: 927-8
52. Giannakopoulos X, Baltogiannis D, Giannakis D, et al The lipidosterolic extract of Serenoa repens in the treatment of benign prostatic hyperplasia: a comparison of two dosage regimens. Adv Ther 2002; 19: 285-96
53. Gerber GS, Zagaja GP, Bales GT, et al. Saw palmetto (Serenoa repens) in men with lower urinary tract symptoms: effects on urodynamic parameters and voiding symptoms. Urology 1998; 51: 1003-7
54. Vohra S, Johnston BC, Cramer K, et al. Adverse events associated with pediatric spinal manipulation: a systematic review. Pediatrics 2007; 119: 275-83
55. Gagnier JJ, Boon H, Rochon P, et al. Recommendations for reporting randomized controlled trials of herbal interventions: explanation and elaboration. J Clin Epidemiol 2006; 59: 1134-49